Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
54.31
+0.77 (1.44%)
Jul 9, 2025, 10:19 AM - Market open
Exact Sciences Employees
Exact Sciences had 7,000 employees as of December 31, 2024. The number of employees increased by 400 or 6.06% compared to the previous year.
Employees
7,000
Change (1Y)
400
Growth (1Y)
6.06%
Revenue / Employee
$404,018
Profits / Employee
-$145,692
Market Cap
10.24B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,000 | 400 | 6.06% |
Dec 31, 2023 | 6,600 | 200 | 3.13% |
Dec 31, 2022 | 6,400 | -100 | -1.54% |
Dec 31, 2021 | 6,500 | 1,500 | 30.00% |
Dec 31, 2020 | 5,000 | 890 | 21.65% |
Dec 31, 2019 | 4,110 | 2,133 | 107.89% |
Dec 31, 2018 | 1,977 | 709 | 55.91% |
Dec 31, 2017 | 1,268 | 532 | 72.28% |
Dec 31, 2016 | 736 | 59 | 8.71% |
Dec 31, 2015 | 677 | 441 | 186.86% |
Dec 31, 2014 | 236 | 134 | 131.37% |
Dec 31, 2013 | 102 | 15 | 17.24% |
Dec 31, 2012 | 87 | 26 | 42.62% |
Dec 31, 2011 | 61 | 26 | 74.29% |
Dec 31, 2010 | 35 | 16 | 84.21% |
Dec 31, 2009 | 19 | 15 | 375.00% |
Dec 31, 2008 | 4 | -10 | -71.43% |
Dec 31, 2007 | 14 | -8 | -36.36% |
Dec 31, 2006 | 22 | -27 | -55.10% |
Dec 31, 2005 | 49 | -22 | -30.99% |
Dec 31, 2004 | 71 | -11 | -13.41% |
Dec 31, 2003 | 82 | 7 | 9.33% |
Dec 31, 2002 | 75 | 7 | 10.29% |
Dec 31, 2001 | 68 | 24 | 54.55% |
Dec 31, 2000 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EXAS News
- 4 hours ago - Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer - Business Wire
- 6 weeks ago - Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap - Business Wire
- 6 weeks ago - Exact Sciences to Participate in June Investor Conference - Business Wire
- 6 weeks ago - Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 - Business Wire
- 2 months ago - Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
- 2 months ago - Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling - Seeking Alpha
- 2 months ago - Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
- 2 months ago - Exact Sciences to Participate in May Investor Conference - Business Wire